Rapid Acting Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global rapid acting insulin market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.61% during 2022-2028. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.
A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.
A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.
Rapid Acting Insulin Market Trends/Drivers:
The Increasing Prevalence of Diabetes Among the Masses
The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.
Continual Technological Advancements
Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient’s overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.
Increasing Awareness and Healthcare Infrastructure
Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.
Rapid Acting Insulin Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
Lispro Insulin
Aspart Insulin
Glulisine Insulin
Lispro insulin dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.
Lispro insulin’s popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.
Breakup by Indication:
Type 1 Diabetes
Type 2 Diabetes
Type 2 diabetes hold the largest share in the market
A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.
Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Drug stores and retail pharmacies hold the largest share in the market
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.
Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.
Competitive Landscape:
Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Adocia
Biocon Limited
Eli Lilly and Company
Gan & Lee Pharmaceuticals Co. Ltd.
Geropharm
MannKind Corporation
Merck & Co. Inc.
Novo Nordisk A/S,
Sanofi S.A.
Wockhardt Ltd.
Recent Developments:
In November 2022, Biocon Limited Completes Acquisition of Viatris’ Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.
In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.
In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.
Key Questions Answered in This Report:
How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
What are the key regional markets?
Which countries represent the most attractive rapid acting insulin market?
What is the breakup of the market based on the product?
Which is the most attractive product in the rapid acting insulin market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the rapid acting insulin market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the rapid acting insulin market?
What is the competitive structure of the global rapid acting insulin market?
Who are the key players/companies in the global rapid acting insulin market?
A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.
A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.
Rapid Acting Insulin Market Trends/Drivers:
The Increasing Prevalence of Diabetes Among the Masses
The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.
Continual Technological Advancements
Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient’s overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.
Increasing Awareness and Healthcare Infrastructure
Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.
Rapid Acting Insulin Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
Lispro Insulin
Aspart Insulin
Glulisine Insulin
Lispro insulin dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.
Lispro insulin’s popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.
Breakup by Indication:
Type 1 Diabetes
Type 2 Diabetes
Type 2 diabetes hold the largest share in the market
A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.
Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Drug stores and retail pharmacies hold the largest share in the market
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.
Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.
Competitive Landscape:
Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Adocia
Biocon Limited
Eli Lilly and Company
Gan & Lee Pharmaceuticals Co. Ltd.
Geropharm
MannKind Corporation
Merck & Co. Inc.
Novo Nordisk A/S,
Sanofi S.A.
Wockhardt Ltd.
Recent Developments:
In November 2022, Biocon Limited Completes Acquisition of Viatris’ Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.
In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.
In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.
Key Questions Answered in This Report:
How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
What are the key regional markets?
Which countries represent the most attractive rapid acting insulin market?
What is the breakup of the market based on the product?
Which is the most attractive product in the rapid acting insulin market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the rapid acting insulin market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the rapid acting insulin market?
What is the competitive structure of the global rapid acting insulin market?
Who are the key players/companies in the global rapid acting insulin market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL RAPID ACTING INSULIN MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT
6.1 Lispro Insulin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Aspart Insulin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Glulisine Insulin
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY INDICATION
7.1 Type 1 Diabetes
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Type 2 Diabetes
7.2.1 Market Trends
7.2.2 Market Forecast
8 MARKET BREAKUP BY DISTRIBUTION CHANNEL
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Adocia
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Biocon Limited
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Eli Lilly and Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Geropharm
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 MannKind Corporation
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Merck & Co. Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Novo Nordisk A/S
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi S.A.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Wockhardt Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL RAPID ACTING INSULIN MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT
6.1 Lispro Insulin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Aspart Insulin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Glulisine Insulin
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY INDICATION
7.1 Type 1 Diabetes
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Type 2 Diabetes
7.2.1 Market Trends
7.2.2 Market Forecast
8 MARKET BREAKUP BY DISTRIBUTION CHANNEL
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Adocia
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Biocon Limited
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Eli Lilly and Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Geropharm
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 MannKind Corporation
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Merck & Co. Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Novo Nordisk A/S
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi S.A.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Wockhardt Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
LIST OF TABLES
Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2023-2028
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2023-2028
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players
Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2023-2028
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2023-2028
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players
LIST OF FIGURES
Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2022
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2022
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2022
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2022
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis
Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2022
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2022
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2022
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2022
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis
